Tempus AI (NASDAQ:TEM) CEO Eric Lefkofsky Sells 166,250 Shares of Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Eric Lefkofsky sold 166,250 shares of Tempus AI stock in a transaction on Monday, June 29th. The stock was sold at an average price of $57.48, for a total transaction of $9,556,050.00. Following the sale, the chief executive officer owned 8,775,283 shares of the company’s stock, valued at $504,403,266.84. The trade was a 1.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tempus AI Price Performance

NASDAQ TEM opened at $61.60 on Thursday. The stock’s fifty day moving average price is $50.28 and its 200 day moving average price is $54.60. The company has a market cap of $11.06 billion, a price-to-earnings ratio of -35.81 and a beta of 3.45. Tempus AI, Inc. has a 1 year low of $41.73 and a 1 year high of $104.32. The company has a debt-to-equity ratio of 2.96, a current ratio of 3.31 and a quick ratio of 3.15.

Tempus AI (NASDAQ:TEM) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.08. The company had revenue of $348.12 million during the quarter, compared to analyst estimates of $345.44 million. Tempus AI had a negative net margin of 22.20% and a negative return on equity of 53.83%. Tempus AI’s revenue for the quarter was up 36.1% compared to the same quarter last year. During the same period last year, the firm posted ($0.24) EPS. As a group, equities research analysts forecast that Tempus AI, Inc. will post -1.35 earnings per share for the current year.

Tempus AI News Summary

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Analyst-style coverage argued Tempus AI remains attractive because of diagnostics momentum, AI platform expansion, and recent FDA-related product gains that may broaden future growth. Tempus AI: Buy On Diagnostics Momentum And AI Platform Expansion
• Positive Sentiment: Some market commentary suggested the recent pullback may be creating a buying opportunity for investors who believe in Tempus AI’s long-term growth story. Tempus AI stock faces a make-or-break moment after its recent pullback
• Neutral Sentiment: Konica Minolta completed the sale of Tempus shares it previously received, which may remove a supply overhang but is not an operating update. Konica Minolta Completes Sale of Tempus Shares to Bolster Balance Sheet
• Negative Sentiment: Biovica said it is refocusing its U.S. commercial strategy and terminating its agreement with Tempus AI, which could reduce a partnership-related opportunity. Biovica Refocuses US Commercial Strategy and Terminates Agreement with Tempus AI
• Negative Sentiment: Recent insider selling by the CFO, CEO, and a director may be pressuring sentiment, even though the trades were made under pre-arranged plans. Tempus AI CEO insider sale filing

Analysts Set New Price Targets

TEM has been the subject of several analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Tempus AI in a report on Wednesday, June 17th. Guggenheim lowered their price objective on Tempus AI from $95.00 to $60.00 and set a “buy” rating on the stock in a research report on Monday, March 30th. Wolfe Research assumed coverage on shares of Tempus AI in a research note on Tuesday, June 2nd. They set a “peer perform” rating on the stock. Freedom Capital upgraded shares of Tempus AI to a “hold” rating in a research note on Tuesday. Finally, HC Wainwright lowered their price target on shares of Tempus AI from $95.00 to $64.00 and set a “buy” rating on the stock in a report on Monday, May 11th. Nine analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Tempus AI presently has a consensus rating of “Hold” and an average price target of $68.54.

Institutional Trading of Tempus AI

Several institutional investors have recently bought and sold shares of TEM. Victory Capital Management Inc. raised its stake in shares of Tempus AI by 1.5% during the 3rd quarter. Victory Capital Management Inc. now owns 11,078 shares of the company’s stock worth $894,000 after buying an additional 162 shares during the period. US Bancorp DE grew its stake in Tempus AI by 6.6% in the 3rd quarter. US Bancorp DE now owns 2,848 shares of the company’s stock valued at $230,000 after acquiring an additional 176 shares during the period. Legacy Bridge LLC increased its holdings in Tempus AI by 1.6% in the 4th quarter. Legacy Bridge LLC now owns 12,418 shares of the company’s stock worth $733,000 after acquiring an additional 193 shares in the last quarter. Truist Financial Corp increased its holdings in Tempus AI by 5.8% in the 4th quarter. Truist Financial Corp now owns 3,532 shares of the company’s stock worth $209,000 after acquiring an additional 194 shares in the last quarter. Finally, Farther Finance Advisors LLC raised its position in Tempus AI by 3.5% during the fourth quarter. Farther Finance Advisors LLC now owns 6,390 shares of the company’s stock worth $377,000 after acquiring an additional 219 shares during the period. 24.22% of the stock is owned by institutional investors and hedge funds.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.